scholarly journals Pharmacoeconomic analysis of the use of granulocyte colonystimulating factor drugs in prophylaxis of febrile neutropenia in cancer patients under healthcare settings in the Russian Federation

2016 ◽  
Vol 4 (1) ◽  
pp. 195-201 ◽  
Author(s):  
A.Yu. Kulikov ◽  
D.T. Ugrekhelidze ◽  
V.B. Larionova ◽  
A.V. Snegovoy
Keyword(s):  
Febrile Neutropenia ◽  
Cancer Patients ◽  
Russian Federation ◽  
Pharmacoeconomic Analysis ◽  
Healthcare Settings ◽  
Colonystimulating Factor ◽  
The Russian Federation

scholarly journals EVALUATION OF THE CLINICAL AND ECONOMIC EFFECTIVENESS OF INTERFERON-GAMMA IN THE TREATMENT OF TUBERCULOSIS

2017 ◽  
Vol 22 (6) ◽  
pp. 276-280
Author(s):  
S. L Plavinskiy ◽  
Pavel I. Shabalkin
Keyword(s):  
Quality Of Life ◽  
Drug Resistance ◽  
Economic Evaluation ◽  
Health System ◽  
Interferon Gamma ◽  
Russian Federation ◽  
Pharmacoeconomic Analysis ◽  
Treatment Regimens ◽  
The Russian Federation

Tuberculosis worldwide is a serious problem for the health system and for society. Despite the fact that in recent years there has been a tendency to the decline in the incidence of tuberculosis, it remains to be one of the socially significant infections in the Russian Federation. Significant difficulties in the treatment of tuberculosis include the overcoming of the drug resistance of mycobacteria to the existing therapy, as well as the available limitations of the resources of the healthcare system in the Russian Federation. In this regard, there is a need to find additional opportunities to improve the effectiveness of the treatment and clinical and economic evaluation of existing treatment regimens. Interferon-gamma is an effective preparation for the management of tuberculosis. As a result of the pharmacoeconomic analysis, the administration of interferon-gamma (Ingaron) contributed to an increase in the quality of life by 2.1 QALY, and in terms of an addition to the therapy will be accompanied by savings of the budget of the Russian Federation up to 284 million rubles, or up to 27.3% of funds for the treatment of patients from this group.

scholarly journals Characteristics of BRCA-associated breast cancer in the population of the Russian Federation

2021 ◽  
Author(s):  
EI Novikova ◽  
EA Kudinova ◽  
VK Bozhenko ◽  
VA Solodkiy
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Russian Federation ◽  
False Negative ◽  
Brca2 Gene ◽  
Breast Cancer Patients ◽  
Brca1 And Brca2 ◽  
Coding Regions ◽  
Brca1 And Brca2 Genes ◽  
The Russian Federation

"Standard" diagnostic panels allow identification of only a few of BRCA1 and BRCA2 gene mutations most common in a population. Therefore, tests relying on such panels may return false negative results, since the coding regions of these genes may have other defects. For breast cancer (BC) patients, false negative test results may translate into selection of inadequate therapy by their doctors. This study aimed to identify the features of BRCA-associated breast cancer in the population of the Russian Federation. The study included breast cancer patients (n = 4440). At the first stage, all patients were screened for the eight most common BRCA1 and BRCA2 genes mutations with the help of real-time PCR. Next, patients that exhibited clinical signs of a hereditary disease (CSHD) in the absence of common mutations (n = 290) had the entire coding regions of BRCA1 and BRCA2 genes studied with next generation sequencing (NGS). "Standard" mutations in the BRCA1 and BRCA2 genes were identified in 169 (3.8%) cases. In the CSHD group, such mutations were revealed in 15.4% of cases. NGS uncovered 33 rare pathogenic BRCA1 and BRCA2 gene mutations in 40 out of 290 breast cancer patients (13.8%). It was concluded that among the residents of the Russian Federation, the range of pathogenic variants of BRCA-associated breast cancer is wide, and it stretches beyond the mutations considered by the "standard" diagnostic panels. Analysis of the entire coding regions of BRCA1 and BRCA2 genes allows increasing efficiency of detection of germline mutations in breast cancer patients at least twofold.

Organizational and legal aspects of the quality of palliative care for cancer patients at the present stage

2020 ◽  
pp. 52-57
Author(s):  
Lyudmila Ertel
Keyword(s):  
Palliative Care ◽  
Law Enforcement ◽  
Cancer Patients ◽  
Social Services ◽  
Russian Federation ◽  
Legal Aspects ◽  
Present Stage ◽  
High Quality ◽  
The Russian Federation

This article discusses some of results of the change in legislation governing the provision of palliative care for cancer patients. Patients are provided with medical and social services with consideration of their individual needs. Priority of social home services for patients remains when determining the form of social services. It is noted that some measures have been taken to organize affordable and high-quality palliative care to eliminate legislative and law-enforcement difficulties in the Russian Federation at the present stage.

Sign in / Sign up

Export Citation Format

Share Document